Literature DB >> 21077276

Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener’s granulomatosis.

B F Bruner1, E S Vista, D M Wynn, J B Harley, J A James.   

Abstract

Many patients with Wegener’s granulomatosis (WG) have anti-neutrophil cytoplasmic antibodies (c-ANCA). Aside from being a diagnostic marker, these autoantibodies may play roles in disease pathogenesis. Proteinase 3 (PR3) is the primary target of c-ANCA in WG patient sera. Of 60 c-ANCA-positive patients, 10 patients were selected for detailed humoral epitope analysis, contingent upon serum availability, using samples with positive levels of anti-PR3 by enzyme-linked immunosorbent assay (ELISA). Sequential epitope specificities of anti-PR3 antibodies detected by screening the maximally overlapping solid-phase octapeptides of PR3 showed seven major common antigenic targets bound by WG patient sera. These include novel and previously identified sequential PR3 epitopes bound by c-ANCA. B cell epitope prediction algorithms identified all or part of the seven defined epitopes. Several epitopes share sequence and structural proximity with functional sites, including the catalytic triad and proposed binding sites of other potential proteins [PR3 complementary peptide and soluble endothelial protein C receptor (sEPCR)]. Epitope 4 (VVLGAHNVRTQ) had the highest binding prevalence (90%) and epitope 2 (AQPHSRPYMAS) has the highest average reactivity of the antigenic regions. Epitope 4 includes the interaction site between sEPCR and PR3 which may serve as an important interaction to down-regulate inflammation. Epitopes 3, 5 and 7 are in direct proximity to amino acids that form the catalytic triad of the protein. c-ANCA targets both unique and previously known sequential PR3 peptides. This information may prove useful in understanding anti-PR3-mediated disease pathogenesis in systemic vasculitides.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21077276      PMCID: PMC2996593          DOI: 10.1111/j.1365-2249.2010.04251.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.

Authors:  J-S F Sanders; M G Huitma; C G M Kallenberg; C A Stegeman
Journal:  Rheumatology (Oxford)       Date:  2006-01-06       Impact factor: 7.580

2.  BALLView: an object-oriented molecular visualization and modeling framework.

Authors:  Andreas Moll; Andreas Hildebrandt; Hans-Peter Lenhof; Oliver Kohlbacher
Journal:  J Comput Aided Mol Des       Date:  2006-02-10       Impact factor: 3.686

3.  Human lupus anti-spliceosome A protein autoantibodies bind contiguous surface structures and segregate into two sequential epitope binding patterns.

Authors:  J A James; J B Harley
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

4.  Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis.

Authors:  G S Kerr; T A Fleisher; C W Hallahan; R Y Leavitt; A S Fauci; G S Hoffman
Journal:  Arthritis Rheum       Date:  1993-03

5.  Plasma levels of endothelial protein C receptor respond to anticoagulant treatment.

Authors:  Deborah J Stearns-Kurosawa; Kandice Swindle; Armando D'Angelo; Patrizia Della Valle; Annalisa Fattorini; Nathalie Caron; Marc Grimaux; Barry Woodhams; Shinichiro Kurosawa
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

6.  Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis.

Authors:  B Nölle; U Specks; J Lüdemann; M S Rohrbach; R A DeRemee; W L Gross
Journal:  Ann Intern Med       Date:  1989-07-01       Impact factor: 25.391

7.  Vasculitis syndromes: LAMP-2 illuminates pathogenesis of ANCA glomerulonephritis.

Authors:  Xavier Bosch; Eduard Mirapeix
Journal:  Nat Rev Nephrol       Date:  2009-05       Impact factor: 28.314

8.  Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils.

Authors:  N Hu; J Westra; M G Huitema; M Bijl; E Brouwer; C A Stegeman; P Heeringa; P C Limburg; C G M Kallenberg
Journal:  Arthritis Rheum       Date:  2009-05

9.  Novel effects of neutrophil-derived proteinase 3 and elastase on the vascular endothelium involve in vivo cleavage of NF-kappaB and proapoptotic changes in JNK, ERK, and p38 MAPK signaling pathways.

Authors:  Gloria A Preston; Christopher S Zarella; William F Pendergraft; Earl H Rudolph; Jia Jin Yang; Stephen B Sekura; J Charles Jennette; Ronald J Falk
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

10.  Cloning of cDNA for proteinase 3: a serine protease, antibiotic, and autoantigen from human neutrophils.

Authors:  D Campanelli; M Melchior; Y Fu; M Nakata; H Shuman; C Nathan; J E Gabay
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  4 in total

1.  Induction of proteinase 3-anti-neutrophil cytoplasmic autoantibodies by proteinase 3-homologous bacterial protease in mice.

Authors:  Yong Chul Kim; Yun Sik Choi; Jehan Alam; Yun-Ji Kim; Keum Jin Baek; Jaemoon Koh; Yeong Wook Song; Doo-Hyun Chung; Youngnim Choi
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

2.  Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes.

Authors:  B F Bruner; E S Vista; D M Wynn; J A James
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

3.  Human Proteinase 3, an important autoantigen of c-ANCA associated vasculitis, shares cross-reactive epitopes with serine protease allergens from mites: an in silico analysis.

Authors:  Emiro Buendía; Múnera Marlon; Orlando Parra; María Sánchez; Andrés Sánchez; Jorge Sánchez; Diego Viasus
Journal:  F1000Res       Date:  2021-01-26

4.  ANCA associated vasculitis in patients from Saudi Arabia.

Authors:  Abdurhman Saud Al Arfaj; Najma Khalil
Journal:  Pak J Med Sci       Date:  2018 Jan-Feb       Impact factor: 1.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.